Levetiracetam (All indications)

Low Apgar score (< 7) (at 5 min)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9029
R30782		 Bank (Levetiracetam) (Mixed indications), 2017 Apgar < 7 at 5 minutes during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 5.46 [0.10;300.64] C 0/7   0/36 0 7
ref
S8983
R30478		 Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 5-min Apgar <7 3rd trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.60 [0.08;32.84] C
excluded (control group) 		0/12   3/132 3 12
ref
S8984
R30490		 Artama (Levetiracetam) (Controls unexposed, disease free), 2013 5-min Apgar <7 3rd trimester population based cohort retrospective unexposed, disease free excluded Adjustment: No 3.84 [0.23;65.16] C
excluded (control group) 		0/12   3,014/269,151 3,014 12
ref
S8985
R30502		 Artama (Levetiracetam) (Controls unexposed, sick), 2013 5-min Apgar <7 3rd trimester population based cohort retrospective unexposed, sick Adjustment: No 8.06 [0.39;165.09] C 0/12   3/652 3 12
ref
Total 2 studies 7.00 [0.63;78.08] 3 19
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bank (Levetiracetam) (Mixed indications), 2017Bank, 2017 1 5.46[0.10; 300.64]0736%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Levetiracetam) (Controls unexposed, sick), 2013Artama, 2013 2 8.06[0.39; 165.09]31264%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 7.00[0.63; 78.08]3190.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Mixed indications; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 7.00[0.63; 78.08]3190%NABank (Levetiracetam) (Mixed indications), 2017 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 8.06[0.39; 165.09]312 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 exposed to other treatment, sickexposed to other treatment, sick 5.46[0.10; 300.64]-7 -NABank (Levetiracetam) (Mixed indications), 2017 1 Tags Adjustment   - No  - No 7.00[0.63; 78.08]3190%NABank (Levetiracetam) (Mixed indications), 2017 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 All studiesAll studies 7.00[0.63; 78.08]3190%NABank (Levetiracetam) (Mixed indications), 2017 Artama (Levetiracetam) (Controls unexposed, sick), 2013 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8983, 8984

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 3.84[0.23; 65.16]3,01412 -NAArtama (Levetiracetam) (Controls unexposed, disease free), 2013 1 unexposed, sick controlsunexposed, sick controls 8.06[0.39; 165.09]312 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.49[0.22; 27.88]3190%NABank (Levetiracetam) (Mixed indications), 2017 Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 20.510.01.0